Ubs Group Ag Insmed Inc Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

A detailed history of Ubs Group Ag transactions in Insmed Inc stock. As of the latest transaction made, Ubs Group Ag holds 128,200 shares of INSM stock, worth $9.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

128,200

Previous 381,063 66.36%

Holding current value

$9.34 Million

Previous $10.3 Million 16.92%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$22.0 - $69.71 $3.24 Million - $10.3 Million	-147,074 Reduced 38.6%	233,989 $15.7 Million
Q1 2024 May 13, 2024	BUY	$25.72 - $29.94 $2.08 Million - $2.42 Million	80,882 Added 26.94%	381,063 $10.3 Million
Q4 2023 Feb 09, 2024	BUY	$23.42 - $31.74 $4.17 Million - $5.65 Million	177,981 Added 145.65%	300,181 $9.3 Million
Q3 2023 Nov 09, 2023	SELL	$19.86 - $26.93 $926,329 - $1.26 Million	-46,643 Reduced 27.63%	122,200 $3.09 Million
Q2 2023 Aug 11, 2023	SELL	$16.44 - $21.1 $63,491 - $81,488	-3,862 Reduced 2.24%	168,843 $3.56 Million
Q1 2023 May 12, 2023	SELL	$16.26 - $21.73 $2.18 Million - $2.92 Million	-134,193 Reduced 43.73%	172,705 $2.94 Million
Q4 2022 Feb 08, 2023	BUY	$16.98 - $23.15 $4.61 Million - $6.28 Million	271,443 Added 765.6%	306,898 $6.13 Million
Q3 2022 Nov 10, 2022	SELL	$20.88 - $28.21 $864,369 - $1.17 Million	-41,397 Reduced 53.87%	35,455 $763,000
Q2 2022 Aug 10, 2022	SELL	$17.07 - $25.71 $2.42 Million - $3.64 Million	-141,490 Reduced 64.8%	76,852 $1.52 Million
Q1 2022 May 16, 2022	BUY	$20.42 - $28.13 $614,131 - $846,009	30,075 Added 15.97%	218,342 $5.13 Million
Q4 2021 Feb 14, 2022	BUY	$25.89 - $33.45 $2.52 Million - $3.25 Million	97,157 Added 106.64%	188,267 $5.13 Million
Q3 2021 Nov 15, 2021	BUY	$22.46 - $29.47 $1.73 Million - $2.27 Million	77,183 Added 554.2%	91,110 $2.51 Million
Q2 2021 Aug 13, 2021	SELL	$24.17 - $36.01 $894,241 - $1.33 Million	-36,998 Reduced 72.65%	13,927 $396,000
Q1 2021 May 12, 2021	BUY	$32.28 - $44.3 $1.12 Million - $1.53 Million	34,633 Added 212.58%	50,925 $1.73 Million
Q4 2020 Feb 11, 2021	SELL	$31.45 - $40.54 $19,404 - $25,013	-617 Reduced 3.65%	16,292 $542,000
Q3 2020 Nov 12, 2020	BUY	$26.0 - $34.5 $32,318 - $42,883	1,243 Added 7.93%	16,909 $544,000
Q2 2020 Jul 31, 2020	SELL	$14.11 - $29.42 $272,026 - $567,188	-19,279 Reduced 55.17%	15,666 $431,000
Q1 2020 May 01, 2020	BUY	$13.63 - $33.98 $114,900 - $286,451	8,430 Added 31.79%	34,945 $560,000
Q4 2019 Feb 14, 2020	SELL	$16.12 - $24.98 $3.05 Million - $4.72 Million	-189,140 Reduced 87.7%	26,515 $633,000
Q3 2019 Nov 14, 2019	BUY	$15.49 - $25.78 $2.37 Million - $3.94 Million	152,973 Added 244.05%	215,655 $3.8 Million
Q2 2019 Aug 14, 2019	BUY	$23.0 - $32.19 $1.1 Million - $1.54 Million	47,761 Added 320.09%	62,682 $1.6 Million
Q1 2019 May 14, 2019	SELL	$13.91 - $31.15 $2.43 Million - $5.44 Million	-174,777 Reduced 92.13%	14,921 $434,000
Q4 2018 Feb 14, 2019	BUY	$11.6 - $18.7 $1.81 Million - $2.92 Million	156,399 Added 469.68%	189,698 $2.49 Million
Q3 2018 Nov 14, 2018	BUY	$18.95 - $28.08 $288,930 - $428,135	15,247 Added 84.46%	33,299 $674,000
Q2 2018 Aug 14, 2018	SELL	$20.0 - $29.72 $1.99 Million - $2.96 Million	-99,515 Reduced 84.65%	18,052 $427,000
Q1 2018 May 15, 2018	BUY	$21.69 - $32.99 $2.1 Million - $3.2 Million	96,897 Added 468.78%	117,567 $2.65 Million
Q4 2017 Feb 14, 2018	SELL	$26.43 - $31.78 $59,493 - $71,536	-2,251 Reduced 9.82%	20,670 $645,000
Q3 2017 Nov 14, 2017	SELL	$11.61 - $31.21 $25,460 - $68,443	-2,193 Reduced 8.73%	22,921 $715,000
Q2 2017 Aug 14, 2017	SELL	N/A	-9,500 Reduced 27.45%	25,114 $431,000
Q1 2017 Nov 14, 2017	BUY	N/A	34,614	34,614 $606,000

Others Institutions Holding INSM

# of Institutions

447

Shares Held

170M

Call Options Held

5.79M

Put Options Held

5.18M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $9.87B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account